Trial · NCT05579964
The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot
NCT05579964, Phase 2, Phase 3, Completed, National Cardiovascular Center Harapan Kita Hospital Indonesia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot. Trials, record NCT05579964. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05579964
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot
- NCT number
- NCT05579964
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 66 participants, actual
- Lead sponsor
- National Cardiovascular Center Harapan Kita Hospital Indonesia
- Conditions
- Congenital Heart Disease in Children, Cardiopulmonary Bypass, Tetralogy of Fallot
- Interventions
- Dexmedetomidine Hcl 100 Mcg/mL Inj, Placebo
- First posted
- 2022-10-14
- Last updated
- 2023-08-24
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum Troponin I at baseline | 5 minutes after induction of anesthesia (T1) | Troponin I serum concentration will be measured using ELABSCIENCE E-EL-H0649 reagent (ng/mL) |
| Primary | Serum Troponin I at 1 hour after cardiopulmonary bypass | 1 hour after cardiopulmonary bypass (T2) | Troponin I serum concentration will be measured using ELABSCIENCE E-EL-H0649 reagent (ng/mL) |
| Primary | Serum Troponin I at 6 hours after cardiopulmonary bypass | 6 hours after cardiopulmonary bypass (T3) | Troponin I serum concentration will be measured using ELABSCIENCE E-EL-H0649 reagent (ng/mL) |
| Primary | Serum Troponin I at 24 hours after cardiopulmonary bypass | 24 hours after cardiopulmonary bypass (T4) | Troponin I serum concentration will be measured using ELABSCIENCE E-EL-H0649 reagent (ng/mL) |
| Primary | Serum IL-6 at baseline | 5 minutes after induction of anesthesia (T1) | IL-6 serum concentration will measured using RnD Quantikine D6050 IL-6 reagent (pg/mL) |
| Primary | Serum IL-6 at 1 hour after cardiopulmonary bypass | 1 hour after cardiopulmonary bypass (T2) | IL-6 serum concentration will measured using RnD Quantikine D6050 IL-6 reagent (pg/mL) |
| Primary | Serum IL-6 at 6 hours after cardiopulmonary bypass | 6 hours after cardiopulmonary bypass (T3) | IL-6 serum concentration will measured using RnD Quantikine D6050 IL-6 reagent (pg/mL) |
| Primary | Serum IL-6 at 24 hours after cardiopulmonary bypass | 24 hours after cardiopulmonary bypass (T4) | IL-6 serum concentration will measured using RnD Quantikine D6050 IL-6 reagent (pg/mL) |
| Secondary | Cardiac output | 5 minutes after induction of anesthesia (T1), 6 hours (T3), 24 hours (T4), and 48 hours (T5) after cardiopulmonary bypass | Cardiac output will be measured using transthoracic echocardiography (L/min) |
| Secondary | Cardiac Index | 5 minutes after induction of anesthesia (T1), 6 hours (T3), 24 hours (T4), and 48 hours (T5) after cardiopulmonary bypass | Cardiac index will be measured using transthoracic echocardiography (L/min) |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05579964
GET https://conductscience.org/api/trials/v1/NCT05579964/registered